NANOPOROUS STENTS WITH ENHANCED CELLULAR ADHESION AND REDUCED NEOINTIMAL FORMATION

• US 20080086198A1
• Filed: 05/24/2007
• Published: 04/10/2008
• Est. Priority Date: 11/13/2002
• Status: Active Grant

• Current Assignee: University of Virginia Patent Foundation (University of Virginia)
• Original Assignee: University of Virginia Patent Foundation (University of Virginia)
• Inventors: Wamhoff, Brian, Hudson, Matthew, Owens, Gary, Reed, Michael, Spradlin, Joshua, Lye, Whye-Kei, Looi, Kareen
• Granted Patent: US 9,770,349 B2
• Time in Patent Office: Days
• US Class Current: 623/1.39
• CPC Class Codes: A61F 2/82 Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95; for closing wounds, or holding wounds closed A61B17/04 - A61B17/115; dilators A61M29/00
• CPC Class Codes: A61F 2/91 made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
• CPC Class Codes: A61F 2240/001 Designing or manufacturing processes
• CPC Class Codes: A61F 2250/0058 Additional features; Implant or prostheses properties not otherwise provided for

Abstract

The present invention relates generally to medical devices containing nanoporous surfaces and methods for making same. More specifically, the invention relates to implantable vascular stents or other biomedical devices having at least one nanoporous layer that promotes improved cellular adhesion properties that promote healing and long term biocompatibility. In the case of stents, the nanoporous layer promotes re-endothelialization at sites of stent implantation vasculature, improves overall healing, and reduces inflammation and intimal disease progression. The nanoporous layer may be optionally loaded with one or more therapeutic agent to further improve the function of the implanted stent and further augment clinical efficacy.

Claims

1. A medical device for insertion into a body, comprising a medical device having a porous surface exhibiting reduced neointimal formation compared to the same medical device lacking the porous surface.

2. The medical device for insertion into a body as in claim 1, wherein the porous surface is a nanoporous surface.

3. The medical device for insertion into a body as in claim 1, wherein the porous surface is a dealloyed surface.

4. The medical device for insertion into a body as in claim 3, wherein the dealloyed surface is a nanoporous surface.

5. The medical device for insertion into a body as in claim 1, wherein the medical device is a stent.

6. The medical device for insertion into a body as in claim 5, wherein the stent is a coronary stent.

7. The medical device for insertion into a body as in claim 5, wherein the stent further comprises a biodegradable coating bonded to the porous surface.

8. The medical device for insertion into a body as in claim 1, wherein the medical device exhibits a reduced percentage area of stenosis compared to the same medical device lacking the porous surface.

9. The medical device for insertion into a body as in claim 1, wherein the medical device lacks an elutable therapeutic agent.

10. The medical device for insertion into a body as in claim 4, wherein the nanoporous surface contains at least one therapeutic agent.

11. The medical device for insertion into a body as in claim 10, wherein the at least one therapeutic agent is selected from a group consisting of:

actinomycin-D, batimistat, c-myc antisense, dexamethasone, paclitaxel, taxanes, sirolimus, tacrolimus and everolimus, unfractionated heparin, low-molecular weight heparin, enoxaprin, bivalirudin, tyrosine kinase inhibitors, Gleevec, wortmannin, PDGF inhibitors, AG1295, rho kinase inhibitors, Y27632, calcium channel blockers, sphingosine phosphate inhibitors, amlodipine, nifedipine, and ACE inhibitors, synthetic polysaccharides, ticlopinin, dipyridamole, clopidogrel, fondaparinux, streptokinase, urokinase, r-urokinase, r-prourokinase, rt-PA, APSAC, TNK-rt-PA, reteplase, alteplase, monteplase, lanoplase, pamiteplase, staphylokinase, abciximab, tirofiban, orbofiban, xemilofiban, sibrafiban, roxifiban, ABT-578, CCI-779, biolimus-A9, temsirolimus, anti-CD34 antibodies, mycophenolic acid, Vitamin E, omega-3 fatty acids, tempamine, and docetaxel, an agent for altering cytochrome P450 function, cyclosporine, an azole antifungal agent, itraconazole, ketoconazole, a macrolide antibiotic, clarithromycin, erythromycin, troleandomycin, an non-nucleoside reverse transcriptase inhibitor, delavirdine, a protease inhibitor, indinavir, ritonavir, saquinavir, ritonavir, grapefruit juice extract, mifepristone, nefazodone, an anti-restenosis agent, an anti-thrombogenic agent, an antibiotic, an anti-platelet agent, an anti-clotting agent, an anti-inflammatory agent, an anti-neoplastic agent, a chelating agent, penicillamine, triethylene tetramine dihydrochloride, EDTA, DMSA (succimer), deferoxamine mesylate, a radiocontrast agent, a radio-isotope, a prodrug, antibody fragments, antibodies, live cells, therapeutic drug delivery microspheres or microbeads, gene therapy agents, viral vectors and plasmid DNA vectors.